Controversies in the Treatment of Adolescents and Young Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
Punita GroverLori S MufflyPublished in: Current oncology reports (2022)
We explore four areas of active investigation: pediatric-inspired front-line treatment regimens, the optimal time of measurable residual disease (MRD) assessment, the role of hematopoietic stem cell transplant and the optimal salvage therapy for relapsed/refractory B-ALL in AYAs. There has been rapid advancement in the management of ALL in the AYA patient population, which has resulted in improved outcomes. We must build on the successes by continuing to promote multi-center innovative clinical research with clinical trial populations reflecting the AYA ALL patient spectrum. The incorporation of novel targeted immunotherapy into front-line treatment will be transformative and redefine treatment paradigms in the coming years.
Keyphrases
- acute lymphoblastic leukemia
- clinical trial
- gene expression
- randomized controlled trial
- type diabetes
- metabolic syndrome
- combination therapy
- skeletal muscle
- drug delivery
- hematopoietic stem cell
- multiple myeloma
- allogeneic hematopoietic stem cell transplantation
- open label
- sensitive detection
- smoking cessation
- double blind